Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras(G12D) Inhibition in Pancreatic Cancer.

Targeting oncomucin-driven immune suppression enhances K-ras(G12D) inhibitor efficacy in pancreatic cancer by reducing tumor burden and immune checkpoints.

• Why it matters: Understanding how oncoMUCs influence the tumor microenvironment can inform new diagnostic and therapeutic strategies for pancreatic ductal adenocarcinoma, which is often resistant to current treatments.
• What they did: Researchers integrated single-cell RNA sequencing, immunostaining, and murine models to analyze oncomucin diversity, immune suppression mechanisms, and combined pharmacologic targeting of oncoMUCs with K-ras(G12D) inhibition in a syngeneic mouse model.
• The result: Targeting oncoMUCs reduced immune checkpoint expression, increased immune cell infiltration, and improved tumor response to K-ras(G12D) inhibition, highlighting oncoMUCs as promising immune regulators and therapeutic targets.